SCHEMBL345709

SCHEMBL345709

CNC(=O)c1cc(COC(=O)NCCC2(CC(C)C)CCN(C(=O)O)CC2)on1

nearest known ligand 0.37

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.37
RAB9A P51151 9/20 0.35
NPC1 O15118 6/20 0.35
MAPK1 P28482 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HPGD P15428 1/20 0.34
POLB P06746 2/20 0.33
HTT P42858 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
LMNA P02545 1/20 0.31
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL345501 0.90 KMT2A (0.34) ALDH1A1RAB9ANPC1SMN1; SMN2POLB
SCHEMBL345198 0.86 POLB (0.39) ALDH1A1RAB9ANPC1POLBMEN1
SCHEMBL345096 0.79 PKM (0.39) RAB9ANPC1MEN1KMT2A
SCHEMBL345678 0.79 POLB (0.35) ALDH1A1RAB9ANPC1SMN1; SMN2POLB
SCHEMBL9993034 0.77 NAMPT (0.36) ALDH1A1RAB9ANPC1POLBMEN1
SCHEMBL16161826 0.77 KMT2A (0.34) RAB9ANPC1POLBMEN1KMT2A
SCHEMBL346247 0.75 PKM (0.40) RAB9ANPC1POLBMEN1KMT2A
SCHEMBL9994309 0.75 KMT2A (0.37) ALDH1A1RAB9ANPC1SMN1; SMN2MEN1
SCHEMBL344847 0.73 KMT2A (0.42) RAB9ANPC1MEN1KMT2A
Hydrochloric Acid SCHEMBL346452 0.71 POLB (0.34) ALDH1A1RAB9ANPC1SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2356108-B1 CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-10-15 EP disclosed
US-8716289-B2 Carbamate derivatives of alkyl-heterocycles, preparation thereof and therapeutic use thereof SANOFI (FR) 2014-05-06 US disclosed
US-20120015950-A1 CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2012-01-19 US disclosed
EP-2356108-A1 CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2011-08-17 EP disclosed
WO-2010055267-A1 CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015950-A1 CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF INTS9, CDK8, SCN8A ALDH1A1 2486/4885RAB9A 331/4885NPC1 1821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.